122 related articles for article (PubMed ID: 16673594)
1. Correlation of high-molecular cytokeratin in tissue of prostatic cancer with Gleason score and PSA.
Acimovic M; Govedarevic V; Mitrovic D; Radosavljevic R; Hadzi Djokic J; Tulic C; Dzamic Z; Jovanovic M; Zivkovic K; Babic M; Markovic-Lipkovski J
Acta Chir Iugosl; 2005; 52(4):45-9. PubMed ID: 16673594
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
3. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody.
Oliai BR; Kahane H; Epstein JI
Am J Surg Pathol; 2002 Sep; 26(9):1151-60. PubMed ID: 12218571
[TBL] [Abstract][Full Text] [Related]
4. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
5. Distinguishing Cowper's glands from neoplastic and pseudoneoplastic lesions of prostate: immunohistochemical and ultrastructural studies.
Saboorian MH; Huffman H; Ashfaq R; Ayala AG; Ro JY
Am J Surg Pathol; 1997 Sep; 21(9):1069-74. PubMed ID: 9298883
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
7. Loss of high-molecular-weight cytokeratin antigenicity in prostate tissue obtained by transurethral resections.
Multhaupt HA; Fessler JN; Warhol MJ
Arch Pathol Lab Med; 2000 Dec; 124(12):1764-7. PubMed ID: 11100054
[TBL] [Abstract][Full Text] [Related]
8. Negative 34betaE12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases.
Halushka MK; Kahane H; Epstein JI
Hum Pathol; 2004 Jan; 35(1):43-6. PubMed ID: 14745723
[TBL] [Abstract][Full Text] [Related]
9. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
10. Atypical cribriform lesions on prostate biopsy.
Kronz JD; Shaikh AA; Epstein JI
Am J Surg Pathol; 2001 Feb; 25(2):147-55. PubMed ID: 11176063
[TBL] [Abstract][Full Text] [Related]
11. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
Jiang Z; Wu CL; Woda BA; Dresser K; Xu J; Fanger GR; Yang XJ
Am J Surg Pathol; 2002 Sep; 26(9):1169-74. PubMed ID: 12218573
[TBL] [Abstract][Full Text] [Related]
12. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies.
Wu HH; Lapkus O; Corbin M
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):285-9. PubMed ID: 15536326
[TBL] [Abstract][Full Text] [Related]
14. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.
Allan RW; Sanderson H; Epstein JI
J Urol; 2003 Aug; 170(2 Pt 1):370-2. PubMed ID: 12853777
[TBL] [Abstract][Full Text] [Related]
15. Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration.
Renshaw AA; Granter SR
Diagn Cytopathol; 2000 Sep; 23(3):199-201. PubMed ID: 10945910
[TBL] [Abstract][Full Text] [Related]
16. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
17. [Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S].
Xiao Q; Yin H; Lu Z; Meng K; Zhou X
Zhonghua Nan Ke Xue; 2004 May; 10(5):362-5. PubMed ID: 15190830
[TBL] [Abstract][Full Text] [Related]
18. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
[TBL] [Abstract][Full Text] [Related]
19. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
20. Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8.
Ljung G; Norberg M; Holmberg L; Busch C; Nilsson S
Prostate; 1997 May; 31(2):91-7. PubMed ID: 9140121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
